Management of Grade 1 Rash with Oral Antihistamines

Introduction to Grade 1 Rash Management

• The Society for Immunotherapy of Cancer recommends oral antihistamines such as cetirizine 10 mg daily or loratadine 10 mg daily for a patient with a Grade 1 rash, which is well within the scope of practice as a provider 1, 2, 3

Grade 1 Rash Management Algorithm

• For Grade 1 rash, the European Society for Medical Oncology suggests continuing the current therapy without interruption or modification of the causative anticancer agent 4, 1, 5
• Grade 1 toxicity does not require dose modification or treatment interruption, as per the European Society for Medical Oncology 4, 5

First-Line Oral Antihistamine Options

• The Society for Immunotherapy of Cancer recommends non-sedating antihistamines, such as cetirizine 10 mg once daily, for daytime use 1, 2, 3, 6
• The European Society for Medical Oncology suggests loratadine 10 mg once daily as an alternative option 7, 1, 2, 3

Topical Therapy

• The Society for Immunotherapy of Cancer recommends concurrent use of topical therapy, including Class I topical corticosteroid for the body and Class V/VI corticosteroid for the face 1, 2, 3
• Emollients with cream or ointment-based, fragrance-free products are also recommended 1, 2, 3

Reassessment Timeline

• The European Society for Medical Oncology suggests reassessing the patient after 2 weeks, either by a healthcare professional or patient self-report 4, 1, 5
• If reactions worsen or do not improve, escalate to Grade 2 management protocols, as per the European Society for Medical Oncology 4, 1, 5

Safety Considerations

• The European Society for Medical Oncology notes that oral antihistamines at standard doses are generally well-tolerated for Grade 1 rash, with cetirizine 10 mg showing no significant difference in adverse events versus placebo 4, 7
• Loratadine 10 mg has minimal adverse events reported, primarily mild sedation in some patients, as per the European Society for Medical Oncology 8, 9

When to Escalate Beyond Your Scope

• The European Society for Medical Oncology recommends considering dermatology referral if there is no improvement or worsening after 2 weeks of Grade 1 management 4, 5
• Progression to Grade 2 or higher toxicity requires escalation of care, as per the Society for Immunotherapy of Cancer and the European Society for Medical Oncology 4, 8, 5, 1, 2, 3